Global Animal Antibacterial and Antibiotics Market 2016-2020
About Animal Antibacterial and Antibiotics
Antibacterial and antibiotic drugs are used to treat various conditions that affect animals such as companion animals, swine, cattle, horses, and fish. These drugs are also used to accelerate the growth of animals, especially in North America and Europe. However, an overuse of antibiotics has led to the development of antibiotic-resistant strains of microorganisms. This is a worrying trend as the resistant microbes could be transferred to humans through the consumption of milk or meat.
Technavio’s analysts forecast the global animal antibacterial and antibiotics market to grow at a CAGR of 6.5% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global animal antibacterial and antibiotics for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs.The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Animal Antibacterial and Antibiotics 2016-2020
Technavio recognizes the following companies as the key players in the global animal antibacterial and antibiotics market: Zoetis, Merck Animal Health, Merial, Elanco, and Bayer HealthCare
Other Prominent Vendors in the market are: Animal Medics, Biogénesis Bagó, Bio-Vet, Boehringer Ingelheim Vetmedica, Ceva Santé Animale, Dechra Pharmaceuticals, ECO Animal Health, Huvepharma, Indian Immunologicals, Lillidale Animal Health, Mobedco-Vet (The Arab Pesticides & Veterinary Drugs), Neogen, Norbrook, Orion, Phibro Animal Health, Vétoquinol, Virbac, and Vitafor.
Commenting on the report, an analyst from Technavio’s team said: “Increase in investments is one of the popular trends of this market. The market is witnessing an increase in investments by various government and non-government organizations such as animal welfare associations. For instance, in 2012, the Animal Health Institute member companies invested $747 million in the R&D of new medicines for animals and the maintenance of existing products. Increased investments, especially in the underdeveloped markets of Asia and Africa, are expected to double the growth rate of the market in these regions.”
According to the report, demand for protein-rich diet will drive growth in the market. Globally, animal products such as milk, eggs, and meat serve a large proportion of the human population. The increase in population is fueling the growth in the demand for food, including animal-based food. Further, the rise in urbanization has created a shift in consumption patterns. Demand for nutrient-dense foods such as animal-based meat and related food items such as milk, egg, and dairy products is on a rise.
Further, the report states that stringent regulatory guidelines for obtaining market approvals of animal drugs are a major hindrance to market growth. In the EU, distinct product supply rules for animal products and language barriers among member states affect the efficient and timely distribution of these drugs. For instance, in Italy, the regulations for the animal healthcare sector are more stringent than for the human healthcare sector, which hinders the regulatory approval process.
Zoetis, Merck Animal Health, Merial, Elanco, Bayer HealthCare, Animal Medics, Biogénesis Bagó, Bio-Vet, Boehringer Ingelheim Vetmedica, Ceva Santé Animale, Dechra Pharmaceuticals, ECO Animal Health, Huvepharma, Indian Immunologicals, Lillidale Animal Health, Mobedco-Vet (The Arab Pesticides & Veterinary Drugs), Neogen, Norbrook, Orion, Phibro Animal Health, Vétoquinol, Virbac, Vitafor.